Replication-deficient modified vaccinia Ankara (MVA) expressing
The compositions and methods are described for generating an immune response to a hemorrhagic fever virus such as ebolavirus, Marburgvirus, or arenavirus. The compositions and methods described herein relate to a modified vaccinia Ankara (MVA) vector encoding one or more viral antigens for generating a protective immune response to a member of genus Ebolavirus (such as a member of species Zaire ebolavirus ), a member of genus Marburgvirus (such as a member of species Marburg marburgvirus ), or a member of genus Arenavirus (such as a member of species Lassa virus ) in the subject to which the vector is administered. The compositions and methods of the present invention are useful both prophylactically and therapeutically and may be used to prevent and/or treat an infection caused by ebolavirus, Marburgvirus, or arenavirus.
1. A recombinant modified vaccinia ankara (MVA) vector comprising:
i) a first nucleic acid encoding a Marburg virus (MARV) glycoprotein, and
ii) a second nucleic acid sequence encoding a Marburg virus (MARV) VP40 matrix protein;
wherein both the first nucleic acid sequence and the second nucleic acid sequence are under the control of one or more promoters compatible with poxvirus expression systems;
wherein the first nucleic acid is located between MVA genes I8R and G1L;
wherein the second nucleic acid sequence is located between MVA genes A50R and B1R in a restructured and modified deletion site III; and
wherein the MARV glycoprotein and the MARV VP40 matrix protein are capable of assembling into virus-like particles (VLPs) when expressed in a host cell.
2. The recombinant MVA vector of claim 1 , wherein the first nucleic acid sequence and the second nucleic acid sequence is optimized by one or more method selected from the group consisting of i) changing selected codons to other synonymous codons that are optimal for protein expression by MVA, ii) interrupting homopolymer stretches using silent mutations, and iii) interrupting transcription terminator motifs using silent mutations.
3. The recombinant MVA vector of claim 1 , wherein the MARV glycoprotein and MARV VP40 matrix protein are derived from the same MARV strain.
4. The recombinant MVA vector of claim 1 , wherein the first nucleic acid sequence comprises nucleic acids 1631-3676 of SEQ ID NO:15, or a nucleic acid sequence at least 95% identical thereto.
5. The recombinant MVA vector of claim 1 , wherein the first nucleic acid sequence comprises nucleic acids 1631-3676 of SEQ ID NO:15.
6. The recombinant MVA vector of claim 1 , wherein the second nucleic acid sequence comprises nucleic acids 1581-2492 of SEQ ID NO:14, or a nucleic acid sequence at least 95% identical thereto.
7. The recombinant MVA vector of claim 1 , wherein the second nucleic acid sequence comprises nucleic acids 1581-2492 of SEQ ID NO:14.
8. The recombinant MVA vector of claim 1 , wherein the first nucleic acid sequence comprises nucleic acids 1631-3676 of SEQ ID NO:15, and the second nucleic acid sequence comprises nucleic acids 1581-2492 of SEQ ID NO:14.
9. A recombinant modified vaccinia ankara (MVA) vector comprising:
i) a first nucleic acid sequence encoding a Marburg virus glycoprotein comprising nucleic acids 1631-3676 of SEQ ID NO:15, or a nucleic acid sequence at least 95% identical thereto, and
ii) a second nucleic acid sequence encoding a Marburg virus VP40 matrix protein comprising nucleic acids 1581-2492 of SEQ ID NO:14, or a nucleic acid sequence at least 95% identical thereto;
wherein both the first nucleic acid sequence and the second nucleic acid sequence are under the control of one or more promoters compatible with poxvirus expression systems;
wherein the first nucleic acid is located between MVA genes I8R and G1L;
wherein the second nucleic acid sequence is located between MVA genes A50R and B1R in a restructured and modified deletion site III; and
wherein the Marburg virus glycoprotein and the Marburg virus VP40 matrix protein are capable of assembling into virus-like particles (VLPs) when expressed in a host cell.
10. A pharmaceutical composition comprising at least one recombinant MVA vector of claim 1 and a pharmaceutically acceptable carrier.
11. A pharmaceutical composition comprising at least one recombinant MVA vector of claim 9 and a pharmaceutically acceptable carrier.